+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 21Years - 65Years
All Genders
ID05018481

Evaluating Sodium Hyaluronate 35kDa Capsules Added to Standard Care in Adults With Alcoholic Hepatitis Over 90 Days

Led by The Cleveland Clinic · Updated on 2026-09-24

54

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of sodium hyaluronate 35kDa HA35 compared to a placebo in adults with alcoholic hepatitis. This early phase 1 study aims to understand how HA35 impacts skeletal muscle mass over 90 days when added to the standard of care treatment. Patients must meet specific clinical criteria related to alcohol consumption and liver function to participate. Participants will be randomly assigned to one of two groups one receiving a daily capsule of HA35 alongside standard care, and the other receiving a placebo capsule with standard care, both for 90 days. The study includes two in-person visits at the start and end of the treatment period, with two additional phone visits at days 30 and 60 to monitor compliance and collect questionnaire data. During visits, participants undergo physical exams, clinical lab tests, body composition scans, muscle strength assessments, and provide urine and stool samples. They will also consume a sugar cocktail to measure gut permeability and have a muscle biopsy taken. The study tracks changes in skeletal muscle mass from baseline to day 90, with careful monitoring through questionnaires and compliance checks. Total participation spans approximately three months.

CONDITIONS

Brief Title

HA35 Moderate Alcoholic Hepatitis (AH) Study

Research Team

S

Srinivasan Dasarathy, MD

A

Annette Bellar

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here